NEW YORK (GenomeWeb News) – Exact Sciences today announced it has expanded its collaboration with Mayo Clinic to include all gastrointestinal cancers and diseases, as well as new cancer screening applications of stool- and blood-based testing.

Exact will still have exclusive rights to commercialize products resulting from the new deal, which builds on a 2009 agreement between it and Mayo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.